Carson Wealth (CWM LLC)
BCRX icon

Carson Wealth (CWM LLC)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.5K Sell
5,931
-2,430
-29% -$18.9K ﹤0.01% 3726
2025
Q4 		$65K Sell
8,361
-21,525
-72% -$156K ﹤0.01% 3406
2025
Q3 		$227K Sell
29,886
-17,449
-37% -$145K ﹤0.01% 2349
2025
Q2 		$424K Sell
47,335
-6,415
-12% -$59.7K ﹤0.01% 1665
2025
Q1 		$403K Buy
53,750
+33,656
+167% +$271K ﹤0.01% 1542
2024
Q4 		$151K Buy
20,094
+3,022
+18% +$22.9K ﹤0.01% 2013
2024
Q3 		$130K Buy
17,072
+11,414
+202% +$86.8K ﹤0.01% 2019
2024
Q2 		$35K Buy
5,658
+3,772
+200% +$20.8K ﹤0.01% 2714
2024
Q1 		$10K Buy
1,886
+322
+21% +$1.81K ﹤0.01% 3312
2023
Q4 		$9K Sell
1,564
-1,967
-56% -$11.4K ﹤0.01% 3225
2023
Q3 		$25K Buy
3,531
+18
+0.5% +$129 ﹤0.01% 2517
2023
Q2 		$25K Sell
3,513
-42
-1% -$337 ﹤0.01% 2471
2023
Q1 		$30K Sell
3,555
-73
-2% -$703 ﹤0.01% 2217
2022
Q4 		$42K Buy
3,628
+215
+6% +$2.68K ﹤0.01% 1838
2022
Q3 		$43K Hold
3,413
– – ﹤0.01% 1727
2022
Q2 		$36K Hold
3,413
– – ﹤0.01% 1776
2022
Q1 		$55K Hold
3,413
– – ﹤0.01% 1559
2021
Q4 		$47K Buy
+3,413
New +$45.2K ﹤0.01% 1592
2021
Q2 		$54K Hold
3,413
– – ﹤0.01% 1370
2021
Q1 		$54K Hold
3,413
– – ﹤0.01% 1370
2020
Q4 		$54K Hold
3,413
– – ﹤0.01% 1370
2020
Q3 		$54K Hold
3,413
– – ﹤0.01% 1370
2020
Q2 		$54K Hold
3,413
– – ﹤0.01% 1370
2020
Q1 		$54K Hold
3,413
– – ﹤0.01% 1370
2019
Q4 		$54K Hold
3,413
– – ﹤0.01% 1370
2019
Q3 		$54K Hold
3,413
– – ﹤0.01% 1370
2019
Q2 		$54K Hold
3,413
– – ﹤0.01% 1370
2019
Q1 		$54K Buy
+3,413
New +$29.2K ﹤0.01% 1370

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Carson Wealth (CWM LLC)'s BCRX Position: Q1 2026 in Review

Carson Wealth (CWM LLC) reduced its BioCryst Pharmaceuticals (BCRX) stake by 29% in Q1 2026, selling an estimated $18.9K and leaving 5,931 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3726.

Carson Wealth (CWM LLC) first reported a position in BCRX in Q1 2019 and has held it in 28 quarters since. The position peaked at $424K in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Carson Wealth (CWM LLC) held 5,931 shares of BioCryst Pharmaceuticals worth $56.5K as of Q1 2026.
  • Carson Wealth (CWM LLC) sold 2,430 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $18.9K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #3726 holding.
  • Carson Wealth (CWM LLC) first reported a position in BioCryst Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • Carson Wealth (CWM LLC)'s BioCryst Pharmaceuticals position peaked at $424K in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.